Stay updated on Autologous TILs in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.

Latest updates to the Autologous TILs in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check13 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check20 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check56 days agoChange DetectedThe webpage has been updated to include new drug information related to metastatic melanoma and other cancers, while significant details about a previous study on adoptive cell therapy have been removed.SummaryDifference23%
- Check63 days agoChange DetectedThe web page has been updated to reflect a new Phase 2 study evaluating adoptive cell therapy (ACT) with TIL (LN-144/LN-145) in combination with immune checkpoint inhibitors for various cancers, including melanoma and non-small cell lung cancer. Key details about patient eligibility, treatment regimens, and study objectives have been added, enhancing the clarity and comprehensiveness of the study information.SummaryDifference28%
Stay in the know with updates to Autologous TILs in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.